Fondazione Centro San Raffaele Del Monte Tabor

Molmed Spa

University of Alberta

Ospedale San Raffaele S.r.l.

Boehringer Biochemia Robin S.p.a.

Fondazione Centro San Raffaele

G. Gaslini Children's Hospital

Fondazione Centro San Raffaele Del Monte

San Raffaele S.r.l.

Angelo Corti

Flavio Curnis

Sergio Tognella

Theresa M Allen

Paola Piro

Cesare Rovelli

Nicola Morgese

Mirco Ponzoni

Carlo Rurali

Emanuela Carta

Sandro Lamponi

Andrés José Maria Ferreri

Rosangela Bassi

The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma.

Combined treatment of primary central nervous system lymphoma

A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.

Immunoconjugates for the treatment of tumours

A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclized by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.

Peptides for inhibiting tumor growth

Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit &#x3b1;v&#x3b2;3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.

Peptides comprising an isoDGR motif

Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.

Modified cytokines for use in cancer therapy

The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.

Tumor-targeted drug delivery systems and uses thereof

Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents ate disclosed.

A device to determine human chorionic gonadotropin (hCG) in urine is described. It includes:

Growing community of inventors

Milan, Italy

Angelo Corti